IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)

Launched by MEDICAL UNIVERSITY OF SOUTH CAROLINA · Aug 30, 2024

Keywords

ClinConnect Summary

The IMPACT trial is studying a mobile app called "Moodivate," designed to help cancer survivors who are dealing with depression or feeling down. The goal of this research is to see if using this app can improve their mood and mental health. If you decide to participate, you'll be randomly placed into one of two groups: about two-thirds of participants will use the Moodivate app, while the remaining third will not use the app at all. Throughout the study, which lasts about 12 weeks, everyone will fill out online questionnaires to share their feelings and experiences.

To be eligible for this study, you need to be over 18 years old, have a smartphone that works with the app, and show signs of depression. You also need to be comfortable using technology and able to communicate in English. While participating in this trial may benefit future cancer survivors, it's important to know that there are some risks, such as feeling frustrated or having your privacy concerns. If you’re interested in other options, you can always talk to your doctor or cancer care team about different treatments for depression.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age \> 18 years
• • ILLIC (as determined during manual chart review)
• • Elevated depressive symptoms, defined as a score of ≥ 8 on the PHQ-9
• • Current owner of an iOS- or Android-compatible smartphone
• • Willingness to utilize a mobile app for the treatment of depressed mood (response of "yes" on yes/no item)
• • Have a valid e-mail address that is checked regularly or have regular access to text messages (to access follow-up assessments)
• • English language fluency
• Exclusion Criteria:
• • Current suicidal ideation at study screening, defined as a response greater than or equal to 1 on item nine of the PHQ-9
• * Severe cognitive impairment that precludes completion of informed consent. For the purposes of assessing eligibility, this criterion is operationalized as:
• • Prior diagnosis of dementia, or Major Neurocognitive Disorder indicated either via self-report or in the EHR; or
• • Self-report of cognitive difficulties that impair functional independence